← All trials
NCT05027451
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 25, 2021
- Primary completion
- Mar 18, 2022
- Completion date
- Mar 18, 2022
- First posted
- Aug 30, 2021
- Last posted
- Nov 15, 2021
- Enrollment
- 9
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- InterveXion Therapeutics, LLCLead sponsor
- National Institute on Drug Abuse (NIDA)Collaborator
- InterveXion Therapeutics, LLCStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.